GLSI Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
["Not a good buy right now for an impatient buyer: near-term technical momentum is weakening (MACD negative and worsening) and pattern-based stats imply a modest downside bias over 1D/1W/1M.", "Despite a bullish longer-term moving-average stack, the stock is currently below the pivot (28.503 vs. ~27.88 post-market), which makes the immediate setup more \u201cwait/hold\u201d than \u201cchase.\u201d", "If already owned, holding is reasonable given the bullish analyst stance and clinical-trial upside, but for new money today the risk/reward is not attractive without a clearer momentum turn."]
["Trend/MAs: Bullish moving-average structure (SMA_5 > SMA_20 > SMA_200) suggests the broader trend has been constructive.", "Momentum: MACD histogram at -0.376 and negatively expanding = bearish/weakening momentum in the near term.", "RSI: RSI_6 at 44.6 (neutral) indicates no oversold bounce signal yet.", "Key levels: Price (~27.88 post) is below Pivot 28.503; nearest support S1 24.08 (then S2 21.347). Resistance levels R1 32.927 and R2 35.66.", "Short-horizon expectation (pattern-based): 60% chance of -0.96% next day, -2.58% next week, -2.7% next month\u2014tilts against buying immediately."]
citing positive Phase 3 FLAMINGO-01 efficacy in the non-HLA-A*02 arm (reported 80% reduction in recurrence in that arm).", "Potential market expansion narrative: analyst commentary suggests the preliminary data could expand the addressable market for GLSI-100.", "Post-market bounce (+3.22%) may indicate some dip-buying after the regular-session drop, though it\u2019s not yet a confirmed trend reversal."]
increases the odds of retesting lower supports (24.08 / 21.
before any sustained move higher.", "News relevance risk: the provided news summary appears to discuss Oncolytics Biotech rather than Greenwich Lifesciences; lack of clear, GLSI-specific fresh catalysts in the news feed reduces near-term momentum support.", "Flow signals: Hedge funds and insiders are described as Neutral with no notable recent activity\u2014no strong \u201csmart money\u201d confirmation."]
["Latest quarter provided: 2025/Q3.", "Revenue: $0 (0.00% YoY) \u2014 consistent with a development-stage biotech (no operating revenue signal).", "Net income: -$4.15M, improved 55.57% YoY (still a loss, but burn/loss narrowed).", "EPS: -$0.30, improved 50% YoY (loss per share narrowed).", "Overall: financials show loss improvement, but the core driver remains clinical/regulatory outcomes rather than near-term fundamentals."]
["Most recent update (2025-12-30): H.C. Wainwright maintained a Buy and raised the price target to $50 from $39.", "Trend: positive revision (price target increase) with rating unchanged at Buy, driven by encouraging Phase 3 arm efficacy commentary.", "Wall Street pro view (pros): strong clinical-efficacy framing and potential market expansion narrative supports upside skew if further data confirm.", "Wall Street con view (cons): limited breadth of coverage in the provided data (effectively a single highlighted firm) and high dependency on trial outcomes make sentiment fragile if data cadence disappoints."]
